Novartis AG
NVS
$119.14
$0.590.50%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.32% | 11.87% | 15.14% | 8.84% | 9.40% |
| Total Other Revenue | 117.22% | 32.99% | 14.73% | 12.58% | 16.88% |
| Total Revenue | 15.26% | 12.38% | 15.13% | 8.93% | 9.60% |
| Cost of Revenue | 4.60% | 4.13% | 28.95% | 3.98% | -5.06% |
| Gross Profit | 18.74% | 15.20% | 11.28% | 10.65% | 15.42% |
| SG&A Expenses | 11.32% | 7.64% | 2.49% | 1.33% | 0.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -101.56% | -60.43% | 123.43% | -97.27% | 169.47% |
| Total Operating Expenses | 5.46% | 0.78% | 66.21% | -15.95% | 0.62% |
| Operating Income | 37.11% | 42.25% | -33.03% | 164.65% | 36.80% |
| Income Before Tax | 17.96% | 40.84% | 38.20% | 118.11% | 43.64% |
| Income Tax Expenses | -14.79% | 80.95% | 278.16% | 412.82% | 47.64% |
| Earnings from Continuing Operations | 23.97% | 34.26% | 6.90% | 110.51% | 42.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 300.00% | -- |
| Net Income | 24.49% | 34.15% | -66.77% | 81.09% | 40.16% |
| EBIT | 37.11% | 42.25% | -33.03% | 164.65% | 36.80% |
| EBITDA | 30.08% | 31.77% | -41.81% | 88.62% | 22.72% |
| EPS Basic | 29.92% | 39.33% | -65.72% | 85.60% | 43.60% |
| Normalized Basic EPS | 41.99% | 51.54% | -31.08% | 196.55% | 40.57% |
| EPS Diluted | 29.56% | 38.93% | -65.63% | 84.60% | 43.00% |
| Normalized Diluted EPS | 42.02% | 51.60% | -31.16% | 196.18% | 40.49% |
| Average Basic Shares Outstanding | -4.18% | -3.72% | -3.07% | -2.42% | -2.40% |
| Average Diluted Shares Outstanding | -4.20% | -3.75% | -2.95% | -2.31% | -2.34% |
| Dividend Per Share | -- | -- | -1.44% | -- | -- |
| Payout Ratio | -0.17% | -0.24% | -- | -- | -- |